Repligen Corp (RGEN)

$107.99 -5.61 (-4.94%)
Market Cap 6.54B
Revenue (ttm) 738.26M
Net Income (ttm) 48.89M
EPS (ttm) N/A
PE Ratio 68.59
Forward PE 62.04
Profit Margin 6.62%
Debt to Equity Ratio 0.00
Volume 1,220,318
Avg Vol 1,003,122
Day's Range N/A - N/A
Shares Out 56.41M
Stochastic %K 3%
Beta 1.09
Analysts Strong Sell
Price Target $178.00

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sampl...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 781 250 0111
Fax: 781 250 0115
Address:
Building 1, Suite 100 41 Seyon Street, Waltham, United States
jewell69
jewell69 May. 12 at 7:36 PM
$RGEN re-entry; SO EASY, EVEN A CAVEMAN CAN DO IT 05/12/2026 Buy RGEN REPLIGEN CORP 29 $115.45 -$3,348.05 More 05/04/2026 Sell RGEN REPLIGEN CORP 28 $118.98 $0.08 $3,331.36 More 04/29/2026 Buy RGEN REPLIGEN CORP 28 $112.80 -$3,158.40 More 04/28/2026 Sell RGEN REPLIGEN CORP 28 $117.73 $0.08 $3,296.36 More 04/28/2026 Buy RGEN REPLIGEN CORP 28 $116.98 -$3,275.44 More 04/27/2026 Sell RGEN REPLIGEN CORP 28 $118.07 $0.08 $3,305.88 More 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 12:21 PM
$RGEN Current Stock Price: $123.35 Contracts to trade: $125.0 RGEN May 15 2026 Call Entry: $2.72 Exit: $4.43 ROI: 63% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
vjtweet
vjtweet May. 8 at 4:09 PM
$RGEN has buy order at 128. That is the prior breakout point and the current action says buyers holding strong.
0 · Reply
Estimize
Estimize May. 6 at 10:00 AM
Wall St is expecting 0.46 EPS for $RGEN Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
jewell69
jewell69 May. 5 at 2:36 PM
$RGEN stifel write up today 5/5 after earns out revenue of $194.3M, above Street's $191.7M and our $187.8M, on organic growth of +11% that beat consensus of +10.1% (Stifel: +9.3%). The Q1 performance was attributed to solid broad-based growth in Process Analytics (up a robust >50%) and Chromatography (up >25%) as well as Protein (mid-teens growth) and Filtration (mid-single digit growth). Management also called out recent business updates which included a signed OEM partnership agreement in China (first teased in 4Q25), the launch of their Transformation Office to help accelerate their fit-for-growth and margin expansion goals, and the divestiture of Polymem (generated $7M of revenue and an operating loss in FY25).
0 · Reply
jewell69
jewell69 May. 5 at 2:34 PM
$RGEN missed the boat (UGH!) now 124.55 10:32 am edt 5/5 05/04/2026 Sell Edit cost basis method RGEN REPLIGEN CORP 28 $118.98 $0.08 $3,331.36 More 04/29/2026 Buy RGEN REPLIGEN CORP 28 $112.80 -$3,158.40 also, earns out. stifiel write up. look 4 my next post.
0 · Reply
mikesterz7
mikesterz7 May. 5 at 11:32 AM
$RGEN 🚨🚨🚨 First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic GAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-year Reiterating FY26 organic revenue growth guidance of 9%-13% and increasing adjusted EPS to $1.97-$2.05
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 11:14 AM
$RGEN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.15 up 50.00% YoY • Reported revenue of $194.25M up 14.83% YoY • Repligen reiterated FY26 organic revenue growth guidance of 9%-13% and increased adjusted EPS guidance to $1.97-$2.05. The company also projects full-year gross margin of 53.7%-54.2%.
0 · Reply
jewell69
jewell69 May. 4 at 2:28 PM
GRANDPA HERE: Does anyone remember the tv ads for 'channeling stocks dot com' there was a chalk board with a very smoothe (flat) stock graph that constantly, and exactly going up and down. all u had 2 do was pay channeling stocks dot com. well, I think I found one $RGEN 05/04/2026 Sell Edit cost basis method RGEN REPLIGEN CORP 28 $118.98 $0.08 $3,331.36 More 04/29/2026 Buy RGEN REPLIGEN CORP 28 $112.80 -$3,158.40 More 04/28/2026 Sell RGEN REPLIGEN CORP 28 $117.73 $0.08 $3,296.36 More 04/28/2026 Buy RGEN REPLIGEN CORP 28 $116.98 -$3,275.44 More 04/27/2026 Sell RGEN REPLIGEN CORP 28 $118.07 $0.08 $3,305.88 More 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00
0 · Reply
jewell69
jewell69 Apr. 27 at 4:10 PM
$RGEN quick trade friday / monday 4/24 4/27 04/27/2026 Sell Edit cost basis method RGEN REPLIGEN CORP 28 $118.07 $0.08 $3,305.88 More 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00 More Total $0.08 $64.88
0 · Reply
Latest News on RGEN
Repligen Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 1:00 PM EDT - 1 day ago

Repligen Transcript: Bank of America Global Healthcare Conference 2026

Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

May 7, 2026, 7:30 AM EDT - 6 days ago

Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

Repligen price target raised to $160 from $145 at Barclays

2026-05-07T10:15:25.000Z - 6 days ago

Repligen price target raised to $160 from $145 at Barclays

Repligen price target lowered to $165 from $180 at JPMorgan

2026-05-07T05:58:36.000Z - 6 days ago

Repligen price target lowered to $165 from $180 at JPMorgan

Repligen price target lowered to $142 from $152 at Jefferies

2026-05-05T19:45:16.000Z - 8 days ago

Repligen price target lowered to $142 from $152 at Jefferies

Repligen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 8 days ago

Repligen Earnings Call Transcript: Q1 2026

Repligen raises FY26 EPS view to $1.97-$2.05 from $1.93-$2.10, consensus $1.97

2026-05-05T11:36:57.000Z - 8 days ago

Repligen raises FY26 EPS view to $1.97-$2.05 from $1.93-$2.10, consensus $1.97

Repligen reports Q1 adjusted EPS 48c, consensus 38c

2026-05-05T11:29:52.000Z - 8 days ago

Repligen reports Q1 adjusted EPS 48c, consensus 38c

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

May 5, 2026, 7:00 AM EDT - 8 days ago

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen to Report First Quarter 2026 Financial Results

Apr 22, 2026, 7:30 AM EDT - 21 days ago

Repligen to Report First Quarter 2026 Financial Results

Repligen price target lowered to $145 from $165 at Canaccord

2026-04-20T14:07:14.000Z - 23 days ago

Repligen price target lowered to $145 from $165 at Canaccord

Repligen opens new Training & Innovation Center in Netherlands

2026-04-17T11:44:10.000Z - 26 days ago

Repligen opens new Training & Innovation Center in Netherlands

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Apr 17, 2026, 7:30 AM EDT - 26 days ago

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Repligen initiated with a Buy at Rothschild & Co Redburn

2026-04-17T08:50:51.000Z - 26 days ago

Repligen initiated with a Buy at Rothschild & Co Redburn

Repligen price target lowered to $145 from $175 at Barclays

2026-04-14T10:46:58.000Z - 4 weeks ago

Repligen price target lowered to $145 from $175 at Barclays

Repligen price target lowered to $140 from $170 at Evercore ISI

2026-04-06T12:48:04.000Z - 5 weeks ago

Repligen price target lowered to $140 from $170 at Evercore ISI

Repligen price target raised to $208 from $180 at H.C. Wainwright

2026-03-23T10:11:06.000Z - 7 weeks ago

Repligen price target raised to $208 from $180 at H.C. Wainwright

Repligen Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 18, 2026, 2:15 PM EDT - 2 months ago

Repligen Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Repligen Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

Repligen Transcript: Leerink Global Healthcare Conference 2026

Repligen price target lowered to $195 from $200 at UBS

2026-02-25T13:46:51.000Z - 2 months ago

Repligen price target lowered to $195 from $200 at UBS

Repligen price target lowered to $170 from $180 at Evercore ISI

2026-02-25T13:39:40.000Z - 2 months ago

Repligen price target lowered to $170 from $180 at Evercore ISI

Repligen price target lowered to $180 from $190 at Wells Fargo

2026-02-25T11:54:32.000Z - 2 months ago

Repligen price target lowered to $180 from $190 at Wells Fargo

Repligen price target lowered to $175 from $200 at Barclays

2026-02-25T10:25:31.000Z - 2 months ago

Repligen price target lowered to $175 from $200 at Barclays

Repligen Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 2 months ago

Repligen Earnings Call Transcript: Q4 2025

Repligen reports Q4 adjusted EPS 49c, consensus 44c

2026-02-24T12:37:14.000Z - 2 months ago

Repligen reports Q4 adjusted EPS 49c, consensus 44c

Repligen sees FY26 EPS $1.93-$2.01, consensus $2.07

2026-02-24T12:36:26.000Z - 2 months ago

Repligen sees FY26 EPS $1.93-$2.01, consensus $2.07

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 24, 2026, 7:30 AM EST - 2 months ago

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 10, 2026, 7:30 AM EST - 3 months ago

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Repligen price target raised to $200 from $190 at UBS

2026-01-16T12:20:38.000Z - 4 months ago

Repligen price target raised to $200 from $190 at UBS

Repligen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 4 months ago

Repligen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Jan 6, 2026, 7:30 AM EST - 4 months ago

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Dec 18, 2025, 7:30 AM EST - 5 months ago

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

Dec 16, 2025, 7:30 AM EST - 5 months ago

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

Repligen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 1:20 PM EST - 5 months ago

Repligen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Repligen Corporation to Present at Evercore Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 6 months ago

Repligen Corporation to Present at Evercore Healthcare Conference

Repligen Transcript: Wolfe Research Healthcare Conference 2025

Nov 18, 2025, 12:40 PM EST - 6 months ago

Repligen Transcript: Wolfe Research Healthcare Conference 2025

Repligen Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 8:30 AM EST - 6 months ago

Repligen Transcript: Jefferies London Healthcare Conference 2025

Repligen Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:00 AM EST - 6 months ago

Repligen Transcript: Stifel 2025 Healthcare Conference

Repligen Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 11:00 AM EST - 6 months ago

Repligen Transcript: UBS Global Healthcare Conference 2025

Repligen Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 7 months ago

Repligen Earnings Call Transcript: Q3 2025

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Oct 28, 2025, 7:30 AM EDT - 7 months ago

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Repligen to Report Third Quarter 2025 Financial Results

Oct 15, 2025, 7:30 AM EDT - 7 months ago

Repligen to Report Third Quarter 2025 Financial Results

Repligen Transcript: Bank of America Global Healthcare Conference 2025

Sep 25, 2025, 6:35 AM EDT - 8 months ago

Repligen Transcript: Bank of America Global Healthcare Conference 2025

Repligen Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Repligen Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Repligen Corporation to Present at Upcoming September Conferences

Aug 22, 2025, 7:30 AM EDT - 9 months ago

Repligen Corporation to Present at Upcoming September Conferences

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Repligen Earnings Call Transcript: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 10 months ago

Repligen Earnings Call Transcript: Q2 2025

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Jul 29, 2025, 7:30 AM EDT - 10 months ago

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Repligen to Report Second Quarter 2025 Financial Results

Jul 17, 2025, 7:30 AM EDT - 10 months ago

Repligen to Report Second Quarter 2025 Financial Results

908 Devices Appoints Christopher D. Brown to its Board of Directors

Jun 16, 2025, 8:00 AM EDT - 11 months ago

908 Devices Appoints Christopher D. Brown to its Board of Directors

MASS

Repligen Transcript: 45th Annual William Blair Growth Stock Conference

Jun 3, 2025, 2:20 PM EDT - 1 year ago

Repligen Transcript: 45th Annual William Blair Growth Stock Conference

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

May 27, 2025, 7:30 AM EDT - 1 year ago

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

Repligen Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:35 PM EDT - 1 year ago

Repligen Transcript: RBC Capital Markets Global Healthcare Conference 2025

Repligen Corporation to Present at Upcoming May Investor Conferences

May 7, 2025, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Upcoming May Investor Conferences

Repligen Earnings Call Transcript: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings Call Transcript: Q1 2025

Repligen Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Repligen Reports First Quarter 2025 Financial Results

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Mar 4, 2025, 7:30 AM EST - 1 year ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

MASS

Repligen Earnings Call Transcript: Q4 2024

Feb 20, 2025, 8:30 AM EST - 1 year ago

Repligen Earnings Call Transcript: Q4 2024

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 7:30 AM EST - 1 year ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Repligen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 4:30 PM EST - 1 year ago

Repligen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Repligen Launches the CTech™ SoloVPE® PLUS System

Jan 6, 2025, 7:30 AM EST - 1 year ago

Repligen Launches the CTech™ SoloVPE® PLUS System

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

Dec 16, 2024, 8:11 AM EST - 1 year ago

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BLFS

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Dec 12, 2024, 7:30 AM EST - 1 year ago

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Dec 9, 2024, 7:30 AM EST - 1 year ago

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Repligen Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 20, 2024, 11:00 AM EST - 1 year ago

Repligen Transcript: Stephens 26th Annual Investment Conference | NASH2024

Repligen Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 12:40 PM EST - 1 year ago

Repligen Transcript: Stifel 2024 Healthcare Conference

Repligen Transcript: UBS Global Healthcare Conference 2024

Nov 14, 2024, 10:15 AM EST - 1 year ago

Repligen Transcript: UBS Global Healthcare Conference 2024

Repligen Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Repligen Earnings Call Transcript: Q3 2024

Repligen Corporation to Present at Upcoming Investor Conferences

Nov 5, 2024, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at Upcoming Investor Conferences

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Oct 14, 2024, 11:15 AM EDT - 1 year ago

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Repligen Transcript: 2024 Wells Fargo Healthcare Conference

Sep 6, 2024, 8:45 AM EDT - 1 year ago

Repligen Transcript: 2024 Wells Fargo Healthcare Conference

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Aug 23, 2024, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

Aug 16, 2024, 11:46 AM EDT - 1 year ago

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

MRVI

Repligen Earnings Call Transcript: Q2 2024

Jul 30, 2024, 8:30 AM EDT - 1 year ago

Repligen Earnings Call Transcript: Q2 2024

Repligen Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Repligen Reports Second Quarter 2024 Financial Results

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Jul 29, 2024, 4:00 PM EDT - 1 year ago

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Repligen to Report Second Quarter 2024 Financial Results

Jul 16, 2024, 7:30 AM EDT - 1 year ago

Repligen to Report Second Quarter 2024 Financial Results

Repligen Announces CEO Transition Plan

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Repligen Announces CEO Transition Plan

Repligen Transcript: Jefferies Global Healthcare Conference

Jun 6, 2024, 11:30 AM EDT - 2 years ago

Repligen Transcript: Jefferies Global Healthcare Conference

Repligen Transcript: The 44th Annual William Blair Growth Stock Conference

Jun 5, 2024, 1:00 PM EDT - 2 years ago

Repligen Transcript: The 44th Annual William Blair Growth Stock Conference

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

Repligen Transcript: 2024 Leerink Partners Healthcare Crossroads Conference

May 30, 2024, 9:40 AM EDT - 2 years ago

Repligen Transcript: 2024 Leerink Partners Healthcare Crossroads Conference

Repligen Corporation to Present at Upcoming June Investor Conferences

May 22, 2024, 7:30 AM EDT - 2 years ago

Repligen Corporation to Present at Upcoming June Investor Conferences

Repligen Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 10:30 AM EDT - 2 years ago

Repligen Transcript: 2024 RBC Capital Markets Global Healthcare Conference

Repligen Earnings Call Transcript: Q1 2024

May 1, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings Call Transcript: Q1 2024

Repligen Reports First Quarter 2024 Financial Results

May 1, 2024, 7:30 AM EDT - 2 years ago

Repligen Reports First Quarter 2024 Financial Results

Repligen to Report First Quarter 2024 Financial Results

Apr 17, 2024, 7:30 AM EDT - 2 years ago

Repligen to Report First Quarter 2024 Financial Results

Repligen Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 20, 2024, 3:00 PM EDT - 2 years ago

Repligen Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Repligen Appoints Maggie A. Pax to Board of Directors

Mar 19, 2024, 7:30 AM EDT - 2 years ago

Repligen Appoints Maggie A. Pax to Board of Directors

Repligen Earnings Call Transcript: Q4 2023

Feb 21, 2024, 8:30 AM EST - 2 years ago

Repligen Earnings Call Transcript: Q4 2023

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 7:30 AM EST - 2 years ago

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 7, 2024, 7:30 AM EST - 2 years ago

Repligen to Report Fourth Quarter and Full Year 2023 Financial Results

Repligen Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 5:15 PM EST - 2 years ago

Repligen Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 19, 2023, 7:30 AM EST - 2 years ago

Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

Dec 7, 2023, 7:30 AM EST - 2 years ago

Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements

Repligen Transcript: Stephens Annual Investment Conference | NASH 2023

Nov 16, 2023, 11:00 AM EST - 2 years ago

Repligen Transcript: Stephens Annual Investment Conference | NASH 2023

Repligen Transcript: Stifel 2023 Annual Healthcare Conference

Nov 15, 2023, 8:00 AM EST - 2 years ago

Repligen Transcript: Stifel 2023 Annual Healthcare Conference

UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report

Nov 14, 2023, 2:01 PM EST - 2 years ago

UPDATE – Repligen Announces Publication of the Company's 2022 Sustainability Report

Repligen Announces Publication of the Company's 2022 Sustainability Report

Nov 14, 2023, 7:30 AM EST - 2 years ago

Repligen Announces Publication of the Company's 2022 Sustainability Report

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

Nov 2, 2023, 7:30 AM EDT - 2 years ago

Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device

Repligen Earnings Call Transcript: Q3 2023

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Repligen Earnings Call Transcript: Q3 2023

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

Oct 31, 2023, 7:30 AM EDT - 2 years ago

Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance

jewell69
jewell69 May. 12 at 7:36 PM
$RGEN re-entry; SO EASY, EVEN A CAVEMAN CAN DO IT 05/12/2026 Buy RGEN REPLIGEN CORP 29 $115.45 -$3,348.05 More 05/04/2026 Sell RGEN REPLIGEN CORP 28 $118.98 $0.08 $3,331.36 More 04/29/2026 Buy RGEN REPLIGEN CORP 28 $112.80 -$3,158.40 More 04/28/2026 Sell RGEN REPLIGEN CORP 28 $117.73 $0.08 $3,296.36 More 04/28/2026 Buy RGEN REPLIGEN CORP 28 $116.98 -$3,275.44 More 04/27/2026 Sell RGEN REPLIGEN CORP 28 $118.07 $0.08 $3,305.88 More 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 12:21 PM
$RGEN Current Stock Price: $123.35 Contracts to trade: $125.0 RGEN May 15 2026 Call Entry: $2.72 Exit: $4.43 ROI: 63% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
vjtweet
vjtweet May. 8 at 4:09 PM
$RGEN has buy order at 128. That is the prior breakout point and the current action says buyers holding strong.
0 · Reply
Estimize
Estimize May. 6 at 10:00 AM
Wall St is expecting 0.46 EPS for $RGEN Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
jewell69
jewell69 May. 5 at 2:36 PM
$RGEN stifel write up today 5/5 after earns out revenue of $194.3M, above Street's $191.7M and our $187.8M, on organic growth of +11% that beat consensus of +10.1% (Stifel: +9.3%). The Q1 performance was attributed to solid broad-based growth in Process Analytics (up a robust >50%) and Chromatography (up >25%) as well as Protein (mid-teens growth) and Filtration (mid-single digit growth). Management also called out recent business updates which included a signed OEM partnership agreement in China (first teased in 4Q25), the launch of their Transformation Office to help accelerate their fit-for-growth and margin expansion goals, and the divestiture of Polymem (generated $7M of revenue and an operating loss in FY25).
0 · Reply
jewell69
jewell69 May. 5 at 2:34 PM
$RGEN missed the boat (UGH!) now 124.55 10:32 am edt 5/5 05/04/2026 Sell Edit cost basis method RGEN REPLIGEN CORP 28 $118.98 $0.08 $3,331.36 More 04/29/2026 Buy RGEN REPLIGEN CORP 28 $112.80 -$3,158.40 also, earns out. stifiel write up. look 4 my next post.
0 · Reply
mikesterz7
mikesterz7 May. 5 at 11:32 AM
$RGEN 🚨🚨🚨 First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic GAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-year Reiterating FY26 organic revenue growth guidance of 9%-13% and increasing adjusted EPS to $1.97-$2.05
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 5 at 11:14 AM
$RGEN Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.15 up 50.00% YoY • Reported revenue of $194.25M up 14.83% YoY • Repligen reiterated FY26 organic revenue growth guidance of 9%-13% and increased adjusted EPS guidance to $1.97-$2.05. The company also projects full-year gross margin of 53.7%-54.2%.
0 · Reply
jewell69
jewell69 May. 4 at 2:28 PM
GRANDPA HERE: Does anyone remember the tv ads for 'channeling stocks dot com' there was a chalk board with a very smoothe (flat) stock graph that constantly, and exactly going up and down. all u had 2 do was pay channeling stocks dot com. well, I think I found one $RGEN 05/04/2026 Sell Edit cost basis method RGEN REPLIGEN CORP 28 $118.98 $0.08 $3,331.36 More 04/29/2026 Buy RGEN REPLIGEN CORP 28 $112.80 -$3,158.40 More 04/28/2026 Sell RGEN REPLIGEN CORP 28 $117.73 $0.08 $3,296.36 More 04/28/2026 Buy RGEN REPLIGEN CORP 28 $116.98 -$3,275.44 More 04/27/2026 Sell RGEN REPLIGEN CORP 28 $118.07 $0.08 $3,305.88 More 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00
0 · Reply
jewell69
jewell69 Apr. 27 at 4:10 PM
$RGEN quick trade friday / monday 4/24 4/27 04/27/2026 Sell Edit cost basis method RGEN REPLIGEN CORP 28 $118.07 $0.08 $3,305.88 More 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00 More Total $0.08 $64.88
0 · Reply
jewell69
jewell69 Apr. 24 at 1:37 PM
$RGEN pt 207 as of 3/18/26 on stifel focus list RGEN is one of our Select List picks. The stock has stepped down on headlines and questions related to FDA disruption and new modality therapeutic program uncertainty, but we continue to see a solid path towards revenue reacceleration back into the low/mid double digit-range – and in our view the bioprocess market remains the healthiest area of the life sciences space. Shares have dipped below the multi-year (ex-Covid) average on EV/EBITDA, and are not far from the lows experienced during the trough of the bioproduction market slowdown. While the industry-level conversation will remain active, we think company-specific dynamics for RGEN are solid and that the stock screens are favorable within the Tools group right now.
0 · Reply
jewell69
jewell69 Apr. 24 at 1:35 PM
$RGEN 1st time trade on stifel list. stock lost 8% yesterday 4/23; today is 4/24 at 9:34 am edt 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00
0 · Reply
freeindeed
freeindeed Apr. 23 at 4:54 PM
https://www.marketbeat.com/instant-alerts/filing-mt-bank-corp-purchases-new-holdings-in-repligen-corporation-rgen-2026-04-23/ $RGEN
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 2 at 5:08 PM
$RGEN RSI: 57.29, MACD: -4.3829 Vol: 3.90, MA20: 116.88, MA50: 131.90 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OptionRunners
OptionRunners Mar. 27 at 8:22 PM
2 large trades minutes before the close $ESTA roll/adjustment to the May $45 puts and they're not taking any risk off And a $RGEN May $110 call buyer Have a good weekend!
0 · Reply
Tfizzle
Tfizzle Mar. 8 at 4:08 PM
$RGEN 134 this week
0 · Reply
Tfizzle
Tfizzle Mar. 6 at 8:52 PM
$USO $DJT $QQQ why do I get the feeling with Oil rsi over 80 and overbought that somehow Trump hits pause on WAR over the weekend in full TACO mode? $WHR $RGEN
1 · Reply
Tfizzle
Tfizzle Mar. 5 at 10:52 PM
$RGEN multiple bottom today. Temporary bottom is in. 130’s next week
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 9:20 PM
$RGEN Current Stock Price: $125.83 Contracts to trade: $125.0 RGEN Mar 20 2026 Call Entry: $6.20 Exit: $12.26 ROI: 98% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 26 at 5:39 PM
$RGEN Share Price: $131.48 Contract Selected: Aug 21, 2026 $130 Calls Buy Zone: $14.96 – $18.48 Target Zone: $24.73 – $30.22 Potential Upside: 56% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 12:04 AM
$RGEN RSI: 29.95, MACD: -6.7014 Vol: 7.96, MA20: 141.94, MA50: 155.44 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Feb. 25 at 3:42 PM
$RGEN just delivered the kind of quarter bulls wait for. Q4 EPS topped estimates, and revenues surged 18% Y/Y — driven by solid organic growth and stronger margins heading into 2026. That’s not just a beat… that’s momentum building. 🚀 Discover what’s fueling the growth story here 👉 https://www.zacks.com/stock/news/2874936/repligens-q4-earnings-beat-estimates-revenues-surge-yy?cid=sm-stocktwits-2-2874936-teaser-35074&ADID=SYND_STOCKTWITS_TWEET_2_2874936_TEASER_35074
0 · Reply